Validation of the reconstituted high-density lipoprotein (rHDL) drug delivery platform using dilauryl fluorescein (DLF)

Drug Delivery and Translational Research

Volumn 1, Issue 2, 2011, Pages 113-120

  McConathy, Walter J ^a   Paranjape, Sulabha ^b   Mooberry, Linda ^c   Buttreddy, Sabitha ^b   Nair, Maya ^c   Lacko, Andras G ^c  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b Fort Worth Texas College of Osteopathic Medicine   (United States)

^c UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

Author keywords

Chemotherapy; Controlled release; Drug delivery; Protective transport; Receptor mediated uptake; Reconstituted HDL

Indexed keywords

CHOLESTEROL ESTER; DILAURYLFLUORESCEIN; FLUORESCEIN DERIVATIVE; HIGH DENSITY LIPOPROTEIN; LAURIC ACID DERIVATIVE; NANOPARTICLE; SCAVENGER RECEPTOR BI; UNCLASSIFIED DRUG;

ARTICLE; CHEMICAL COMPOSITION; CONTROLLED STUDY; DENSITY; DRUG DELIVERY SYSTEM; DRUG HYDROLYSIS; DRUG TRANSPORT; DRUG UPTAKE; MOLECULAR WEIGHT; NANOPHARMACEUTICS; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYSTEMIC CIRCULATION; VALIDATION STUDY;

EID: 84861311694     PISSN: 2190393X     EISSN: 21903948     Source Type: Journal    
DOI: 10.1007/s13346-010-0012-0     Document Type: Article

References (38)

1. Brewer Jr HB, Gregg RE, Hoeg JM, Fojo SS. Apolipoproteins and lipoproteins in human plasma: an overview. Clin Chem. 1988; 34(8B): B4-8.
2. Lewis GF, Rader DJ. New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res. 2005; 96: 1221-32.
3. Barter PJ. Hugh Sinclair lecture: the regulation and remodelling of HDL by plasma factors. Atheroscler Suppl. 2002; 3: 39-47.
4. Nofer JR, Kehrel B, Fobker M, Levkau B, Assmann G, von Eckardstein A. HDL and arteriosclerosis: beyond reverse cholesterol transport. Atherosclerosis. 2002; 161: 1-16.
5. Curtiss LK, Valenta DT, Hime NJ, Rye KA. What is so special about apolipoprotein AI in reverse cholesterol transport? Arterioscler Thromb Vasc Biol. 2006; 26: 12-9.
6. Trigatti BL, Krieger M, Rigotti A. Influence of the HDL receptor SR-BI on lipoprotein metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol. 2003; 23: 1732-8.
7. Lacko AG, Nair M, Prokai L, McConathy WJ. Prospects and challenges of the development of lipoprotein-based formulations for anti-cancer drugs. Expert Opin Drug Deliv. 2007; 4: 665-75.
8. Nanjee MN, Cooke CJ, Garvin R, Semeria F, Lewis G, Olszewski WL, et al. Intravenous apoA-I/lecithin discs increase pre-beta-HDL concentration in tissue fluid and stimulate reverse cholesterol transport in humans. J Lipid Res. 2001; 42: 1586-93.
9. Pajkrt D, Lerch PG, van der Poll T, Levi M, Illi M, Doran JE, et al. Differential effects of reconstituted high-density lipoprotein on coagulation, fibrinolysis and platelet activation during human endotoxemia. Thromb Haemost. 1997; 77: 303-7.
10. Kujiraoka T, Hattori H, Ito M, Nanjee MN, Ishihara M, Nagano M, et al. Effects of intravenous apolipoprotein A-I/phosphatidyl choline discs on paraoxonase and platelet-activating factor acetylhydrolase in human plasma and tissue fluid. Atherosclerosis. 2004; 176: 57-62.
11. Counsell RE, Pohland RC. Lipoproteins as potential site-specific delivery systems for diagnostic and therapeutic agents. J Med Chem. 1982; 25: 1115-20.
12. Lacko AG, Nair M, Paranjape S, Johnson S, McConathy WJ. High density lipoprotein complexes as delivery vehicles for cancer chemotherapy. Anti-Cancer. 2002; 22: 2045-9.
13. McConathy WJ, Nair M, Paranjape S, Mooberry L, Lacko AG. Evaluation of synthetic/reconstituted high density lipoproteins (rHDL) as delivery vehicles for paclitaxel. Anticancer Drugs. 2008; 19: 183-8.
14. Zhang Z, Chen J, Ding L, Jin H, Lovell JF, Corbin IR, et al. HDL-mimicking peptide-lipid nanoparticles with improved tumor targeting. Small. 2010; 6: 430-7.
15. Corbin IR, Zheng G. Mimicking nature's nanocarrier: synthetic low-density lipoprotein-like nanoparticles for cancer-drug delivery. Nanomed. 2007; 2: 375-80.
16. Lackó AG, Stewart DR, McClain R, Prókai L, McConathy WJ. Recent developments and patenting of lipoprotein based formulations. Recent Pat Drug Deliv Formul. 2007; 1: 143-5.
17. Mooberry LK, Nair M, Paranjape S, McConathy WJ, Lacko AG. Receptor mediated uptake of paclitaxel from a synthetic high density lipoprotein nanocarrier. J Drug Target. 2010; 18: 53-8.
18. Laggner A, Bastian L, Prager J, Pointner H, Deutsch E. Diagnosis of pancreatic function. Simplified screening with fluorescein dilaurate using serum concentration determinations. Fortschr Med. 1981; 99: 589-91.
19. Meyer-Bertenrath JG. Lipolytic enzymes of the human pancreas. I. A highly sensitive, specific, and simple measurement of cholesterol ester hydrolase activity. Enzyme. 1982; 28: 336-42.
20. Matz C, Jonas A. Micellar complexes of human apolipoprotein A-I with phosphatidylcholines and cholesterol, prepared from cholate-lipid dispersion. J Biol Chem. 1982; 257: 4535-40.
21. Terpstra AHM, Woodward CJH, Sanchez-Muniz FJ. Improved techniques for the separation of serum lipoproteins by density gradient ultracentrifugation. Anal Biochem. 1981; 111: 149-57.
22. Loney WW, Kudchodkar BJ, Weis S, Clearfield MB, Shores J, Lacko AG. Evaluation of gemfibrozil therapy: predictive response from lipoprotein subfraction analysis. Am J Ther. 1997; 4: 301-9.
23. Forte T, Norum KR, Glomset JA, Nichols AV. Plasma lipoproteins in familial lecithin: cholesterol acyltransferase deficiency: structure of low and high density lipoproteins as revealed by electron microscopy. J Clin Invest. 1971; 50: 1141-8.
24. Acton SL, Scherer PE, Lodish HF, Krieger M. Expression cloning of SR-BI, a CD36-related class B scavenger receptor. J Biol Chem. 1994; 269: 21003-9.
25. Arnould R, Dubois J, Abikhalil F, Libert A, Ghanem G, Atassi G, et al. Comparison of two cytotoxicity assays-tetrazolium derivative reduction (MTT) and tritiated thymidine uptake-on three malignant mouse cell lines using chemotherapeutic agents and investigational drugs. Anticancer Res. 1990; 10: 145-54.
26. Urrutia-Rojas X, Menchaca J, Wadley W, Ahmad N, Lacko AG, Bae S, et al. Cardiovascular risk factors in Mexican-Americans at risk for type 2 diabetes mellitus. J Adolesc Health. 2004; 34: 290-9.
27. Kieft KA, Bocan TM, Krause BR. Rapid online determination of cholesterol among plasma lipoproteins after high performance gel filtration chromatography. J Lipid Res. 1991; 32: 859-66.
28. Ackers GK. Analytical gel chromatography of proteins. Adv Protein Chem. 1970; 24: 343-446.
29. Meurs I, van Eck M, van Berkel TJC. High-density lipoprotein: key molecule in cholesterol efflux and the prevention of atherosclerosis. Curr Pharm Des. 2010; 16: 1445-67.
30. Yamashita S, Sakai N, Hirano K, Ishigami M, Maruyama T, Nakajima N, et al. Roles of plasma lipid transfer proteins in reverse cholesterol transport. Front Biosci. 2001; 6: D366-87.
31. Kwong M, Wasan KM. Lipid transfer protein transports compounds from lipid nanoparticles to plasma lipoproteins. Biochem Pharmacol. 2002; 64: 1669-75.
32. Wasan KM, Morton RE, Rosenblum MG, Lopez-Berestein G. Decreased toxicity of liposomal amphotericin B due to association of amphotericin B with high-density lipoproteins: role of lipid transfer protein. J Pharm Sci. 1994; 83: 1006-10.
33. Wasan KM, Morton RE. Differences in lipoprotein concentration and composition modify the plasma distribution of free and liposomal annamycin. Pharm Res. 1996; 13: 462-8.
34. Wasan KM, Brocks DR, Lee SD, Sachs-Barrable K, Thornton SJ. Impact of lipoproteins on the biological activity and disposition of hydrophobic drugs: implications for drug discovery. Nat Rev Drug Discov. 2008; 7: 84-99.
35. Seki J, Sonoke S, Saheki A, Koike T, Fukui H, Doi M, et al. Lipid transfer protein transports compounds from lipid nanoparticles to plasma lipoproteins. Int J Pharm. 2004; 275: 239-48.
36. Lacko AG, Nair M, Paranjape S, Mooberry L, McConathy WJ. Trojan horse meets magic bullet to spawn a novel, highly effective drug delivery model. Chemotherapy. 2006; 52: 171-3.
37. Cao WM, Murao K, Imachi H, Yu X, Abe H, Yamauchi A, et al. A mutant high-density lipoprotein receptor inhibits proliferation of human breast cancer cells. Cancer Res. 2004; 64: 1515-21.
38. Pussinen PJ, Karten B, Wintersperger A, Reicher H, McLean M, Malle E, et al. The human breast carcinoma cell line HBL-100 acquires exogenous cholesterol from high-density lipoprotein via CLA-1 (CD-36 and LIMPII analogous 1)-mediated selective cholesteryl ester uptake. Biochem J. 2000; 349: 559-66.